{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:37:11Z","timestamp":1791041831177,"version":"4.1.0"},"reference-count":184,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>The use of inhibitors of vascular endothelial growth factor (VEGF)\/vascular endothelial growth factor receptor 2 (VEGFR2) signaling for the treatment of cancer has increased over the last decade. This signaling pathway plays a fundamental role in angiogenesis and also in kidney physiology. The emergence of anti-angiogenic therapies has led to adverse nephrotoxic effects, despite improving the outcomes of patients. In this review, we will present the different anti-angiogenic therapies targeting the VEGFR pathway in association with the incidence of renal manifestations during their use. In addition, we will discuss, in detail, the pathophysiological mechanisms of frequent renal diseases such as hypertension, proteinuria, renal dysfunction, and electrolyte disorders. Finally, we will outline the cellular damage described following these therapies.<\/jats:p>","DOI":"10.3390\/diagnostics11040640","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T10:44:01Z","timestamp":1617273841000},"page":"640","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Nephrotoxicity of Anti-Angiogenic Therapies"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8050-6380","authenticated-orcid":false,"given":"Margaux","family":"Van Wynsberghe","sequence":"first","affiliation":[{"name":"INSERM, Institut Mondor de Recherche Biom\u00e9dicale, Paris Est Creteil University, F-94010 Creteil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Flejeo","sequence":"additional","affiliation":[{"name":"INSERM, Institut Mondor de Recherche Biom\u00e9dicale, Paris Est Creteil University, F-94010 Creteil, France"},{"name":"Service de N\u00e9phrologie, CHU Pontchaillou, F-35000 Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Sakhi","sequence":"additional","affiliation":[{"name":"INSERM, Institut Mondor de Recherche Biom\u00e9dicale, Paris Est Creteil University, F-94010 Creteil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3590-706X","authenticated-orcid":false,"given":"Mario","family":"Ollero","sequence":"additional","affiliation":[{"name":"INSERM, Institut Mondor de Recherche Biom\u00e9dicale, Paris Est Creteil University, F-94010 Creteil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dil","family":"Sahali","sequence":"additional","affiliation":[{"name":"INSERM, Institut Mondor de Recherche Biom\u00e9dicale, Paris Est Creteil University, F-94010 Creteil, France"},{"name":"Service de N\u00e9phrologie, AP-HP, Groupe Henri-Mondor Albert-Chenevier, F-94010 Creteil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Izzedine","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Peupliers Private Hospital, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5441-8662","authenticated-orcid":false,"given":"Carole","family":"Henique","sequence":"additional","affiliation":[{"name":"INSERM, Institut Mondor de Recherche Biom\u00e9dicale, Paris Est Creteil University, F-94010 Creteil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35025220","article-title":"Angiogenesis in Cancer and Other Diseases","volume":"407","author":"Carmeliet","year":"2000","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04483","article-title":"Angiogenesis as a Therapeutic Target","volume":"438","author":"Ferrara","year":"2005","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11523-015-0368-7","article-title":"Renal Toxicities of Targeted Therapies","volume":"10","author":"Abbas","year":"2015","journal-title":"Target. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Semeniuk-Wojta\u015b, A., Lubas, A., Stec, R., Szczylik, C., and Niemczyk, S. (2016). Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17122073"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/17512433.2020.1734450","article-title":"Incidence and Risk of Proteinuria Associated with Newly Approved Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: An up-to-Date Meta-Analysis of Randomized Controlled Trials","volume":"13","author":"Zhang","year":"2020","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/s41467-019-09936-x","article-title":"Disruption of Podocyte Cytoskeletal Biomechanics by Dasatinib Leads to Nephrotoxicity","volume":"10","author":"Calizo","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ki.2013.344","article-title":"Expression Patterns of RelA and C-Mip Are Associated with Different Glomerular Diseases Following Anti-VEGF Therapy","volume":"85","author":"Izzedine","year":"2014","journal-title":"Kidney Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrclinonc.2009.130","article-title":"An Overview of Small-Molecule Inhibitors of VEGFR Signaling","volume":"6","author":"Ivy","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrm2183","article-title":"Molecular Regulation of Angiogenesis and Lymphangiogenesis","volume":"8","author":"Adams","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","article-title":"Tumor Angiogenesis","volume":"358","author":"Kerbel","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell Signaling by Receptor Tyrosine Kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41581-020-0260-2","article-title":"Targeting Angiogenesis and Lymphangiogenesis in Kidney Disease","volume":"16","author":"Tanabe","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF Inhibition and Renal Thrombotic Microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.2337\/DB11-1655","article-title":"Vegfa Protects the Glomerular Microvasculature in Diabetes","volume":"61","author":"Sivaskandarajah","year":"2012","journal-title":"Diabetes"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1681\/ASN.2010030295","article-title":"Glomerular Structure and Function Require Paracrine, Not Autocrine, VEGF-VEGFR-2 Signaling","volume":"21","author":"Sison","year":"2010","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Wang, H., Yue, Z., Wu, J., Liu, T., Mo, Y., Jiang, X., and Sun, L. (2015). The Accumulation of VEGFA in the Glomerular Basement Membrane and Its Relationship with Podocyte Injury and Proteinuria in Alport Syndrome. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0135648"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ki.2010.64","article-title":"Overexpression of VEGF-A in Podocytes of Adult Mice Causes Glomerular Disease","volume":"77","author":"Veron","year":"2010","journal-title":"Kidney Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"F1656","DOI":"10.1152\/ajprenal.00275.2009","article-title":"The Balance of Autocrine VEGF-A and VEGF-C Determines Podocyte Survival","volume":"297","author":"Worthmann","year":"2009","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.2337\/db08-0647","article-title":"Inducible Overexpression of SFlt-1 in Podocytes Ameliorates Glomerulopathy in Diabetic Mice","volume":"57","author":"Ku","year":"2008","journal-title":"Diabetes"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"39933","DOI":"10.1074\/jbc.M111.241620","article-title":"Vascular Endothelial Growth Factor Receptor 2 Direct Interaction with Nephrin Links VEGF-A Signals to Actin in Kidney Podocytes","volume":"286","author":"Bertuccio","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1172\/JCI17423","article-title":"Glomerular-Specific Alterations of VEGF-A Expression Lead to Distinct Congenital and Acquired Renal Diseases","volume":"111","author":"Eremina","year":"2003","journal-title":"J. Clin. Invest."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41581-019-0119-6","article-title":"Pre-Eclampsia: Pathogenesis, Novel Diagnostics and Therapies","volume":"15","author":"Phipps","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1172\/JCI17189","article-title":"Excess Placental Soluble Fms-like Tyrosine Kinase 1 (SFlt1) May Contribute to Endothelial Dysfunction, Hypertension, and Proteinuria in Preeclampsia","volume":"111","author":"Maynard","year":"2003","journal-title":"J. Clin. Invest."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1414838","article-title":"Predictive Value of the SFlt-1:PlGF Ratio in Women with Suspected Preeclampsia","volume":"374","author":"Zeisler","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3109\/10641950802631036","article-title":"Glomerular Disturbances in Preeclampsia: Disruption between Glomerular Endothelium and Podocyte Symbiosis","volume":"29","author":"Henao","year":"2010","journal-title":"Hypertens. Pregnancy"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s11906-013-0400-1","article-title":"Proteinuria in Preeclampsia from a Podocyte Injury Perspective","volume":"15","author":"Henao","year":"2013","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrneph.2010.152","article-title":"Endothelial Dysfunction as a Potential Contributor in Diabetic Nephropathy","volume":"7","author":"Nakagawa","year":"2011","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1111\/j.1523-1755.2004.00621.x","article-title":"The Role of Vascular Endothelial Growth Factor (VEGF) in Renal Pathophysiology","volume":"65","author":"Schrijvers","year":"2004","journal-title":"Kidney Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"F422","DOI":"10.1152\/ajprenal.00448.2005","article-title":"Autocrine VEGF-A System in Podocytes Regulates Podocin and Its Interaction with CD2AP","volume":"291","author":"Guan","year":"2006","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_30","first-page":"1449","article-title":"Inhibition of the VEGF Signalling Pathway and Glomerular Disorders","volume":"30","author":"Ollero","year":"2015","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/med.21452","article-title":"Tumor Angiogenesis Revisited: Regulators and Clinical Implications","volume":"37","author":"Ronca","year":"2017","journal-title":"Med. Res. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","article-title":"Hypoxia-Inducible Factor 1 Is a Basic-Helix-Loop-Helix-PAS Heterodimer Regulated by Cellular O2 Tension","volume":"92","author":"Wang","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor Angiogenesis: Therapeutic Implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1681\/ASN.2018080853","article-title":"Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities","volume":"30","author":"Estrada","year":"2019","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-019-0718-5","article-title":"Recent Advances on Anti-Angiogenesis Receptor Tyrosine Kinase Inhibitors in Cancer Therapy","volume":"12","author":"Qin","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.kint.2019.02.042","article-title":"Nephrotoxicity Induced by Intravitreal Vascular Endothelial Growth Factor Inhibitors: Emerging Evidence","volume":"96","author":"Hanna","year":"2019","journal-title":"Kidney Int."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/ckj\/sfaa049","article-title":"Worsening Proteinuria and Renal Function after Intravitreal Vascular Endothelial Growth Factor Blockade for Diabetic Proliferative Retinopathy","volume":"13","author":"Shye","year":"2020","journal-title":"Clin. Kidney J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for Advanced Cervical Cancer: Final Overall Survival and Adverse Event Analysis of a Randomised, Controlled, Open-Label, Phase 3 Trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Gridelli, C., de Castro Carpeno, J., Dingemans, A.-M.C., Griesinger, F., Grossi, F., Langer, C., Ohe, Y., Syrigos, K., Thatcher, N., and Das-Gupta, A. (2018). Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial. JAMA Oncol., 4.","DOI":"10.1001\/jamaoncol.2018.3486"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and Paclitaxel-Carboplatin Chemotherapy and Secondary Cytoreduction in Recurrent, Platinum-Sensitive Ovarian Cancer (NRG Oncology\/Gynecologic Oncology Group Study GOG-0213): A Multicentre, Open-Label, Randomised, Phase 3 Trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","article-title":"Erlotinib plus Bevacizumab versus Erlotinib Alone in Patients with EGFR-Positive Advanced Non-Squamous Non-Small-Cell Lung Cancer (NEJ026): Interim Analysis of an Open-Label, Randomised, Multicentre, Phase 3 Trial","volume":"20","author":"Saito","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11060-020-03404-z","article-title":"Hypertension and Proteinuria as Clinical Biomarkers of Response to Bevacizumab in Glioblastoma Patients","volume":"147","author":"Carvalho","year":"2020","journal-title":"J. Neurooncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1681\/ASN.2010020167","article-title":"Bevacizumab Increases Risk for Severe Proteinuria in Cancer Patients","volume":"21","author":"Wu","year":"2010","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"51492","DOI":"10.18632\/oncotarget.18190","article-title":"Bevacizumab Significantly Increases the Risks of Hypertension and Proteinuria in Cancer Patients: A Systematic Review and Comprehensive Meta-Analysis","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Al-Samkari, H., Kasthuri, R.S., Parambil, J.G., Albitar, H.A., Almodallal, Y.A., V\u00e1zquez, C., Serra, M.M., Dupuis-Girod, S., Wilsen, C.B., and McWilliams, J.P. (2020). An International, Multicenter Study of Intravenous Bevacizumab for Bleeding in Hereditary Hemorrhagic Telangiectasia: The InHIBIT-Bleed Study. Haematologica.","DOI":"10.3324\/haematol.2020.261859"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/neuonc\/nor091","article-title":"A Phase II Trial of Single-Agent Bevacizumab in Patients with Recurrent Anaplastic Glioma","volume":"13","author":"Kreisl","year":"2011","journal-title":"Neuro Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11912-018-0708-8","article-title":"Tyrosine Kinase Inhibitor-Induced Hypertension","volume":"20","author":"Agarwal","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Zhang, Z.-F., Wang, T., Liu, L.-H., and Guo, H.-Q. (2014). Risks of Proteinuria Associated with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090135"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/annonc\/mdr010","article-title":"Sorafenib May Induce Hypophosphatemia through a Fibroblast Growth Factor-23 (FGF23)-Independent Mechanism","volume":"22","author":"Bellini","year":"2011","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/hed.23898","article-title":"Phase II Trial Evaluating the Efficacy of Sorafenib (BAY 43-9006) and Correlating Early Fluorodeoxyglucose Positron Emission Tomography\u2013CT Response to Outcome in Patients with Recurrent and\/or Metastatic Head and Neck Cancer","volume":"38","author":"Lalami","year":"2016","journal-title":"Head Neck"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/annonc\/mdt109","article-title":"Temsirolimus Combined with Sorafenib in Hepatocellular Carcinoma: A Phase I Dose-Finding Trial with Pharmacokinetic and Biomarker Correlates","volume":"24","author":"Kelley","year":"2013","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Terashima, T., Yamashita, T., Takata, N., Takeda, Y., Kido, H., Iida, N., Kitahara, M., Shimakami, T., Takatori, H., and Arai, K. (2020). Safety and Efficacy of Sorafenib Followed by Regorafenib or Lenvatinib in Patients with Hepatocellular Carcinoma. Hepatol. Res. Off. J. Jpn. Soc. Hepatol.","DOI":"10.1111\/hepr.13588"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1470-2045(14)71136-2","article-title":"Sorafenib and Everolimus for Patients with Unresectable High-Grade Osteosarcoma Progressing after Standard Treatment: A Non-Randomised Phase 2 Clinical Trial","volume":"16","author":"Grignani","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1805052","article-title":"Sorafenib for Advanced and Refractory Desmoid Tumors","volume":"379","author":"Gounder","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/jjco\/hyt054","article-title":"Efficacy and Safety of Axitinib versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial","volume":"43","author":"Ueda","year":"2013","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in First-Line Treatment for Advanced Renal Cell Carcinoma: Extended Follow-up of Efficacy and Safety Results from a Randomised, Controlled, Phase 3 Trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_62","first-page":"394","article-title":"Efficacy and Safety of Sunitinib in Elderly Patients with Advanced Renal Cell Carcinoma","volume":"9","author":"Fujita","year":"2018","journal-title":"Mol. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Jin, H., Zhang, J., Shen, K., Hao, J., Feng, Y., Yuan, C., Zhu, Y., and Ma, X. (2019). Efficacy and Safety of Perioperative Appliance of Sunitinib in Patients with Metastatic or Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Medicine, 98.","DOI":"10.1097\/MD.0000000000015424"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/02841860802314720","article-title":"Risk of Hypertension and Renal Dysfunction with an Angiogenesis Inhibitor Sunitinib: Systematic Review and Meta-Analysis","volume":"48","author":"Zhu","year":"2009","journal-title":"Acta Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","article-title":"Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy","volume":"375","author":"Ravaud","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus Bevacizumab versus Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma (IMmotion151): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/jjco\/hyy053","article-title":"Drug Review: Pazopanib","volume":"48","author":"Miyamoto","year":"2018","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S1470-2045(19)30276-1","article-title":"Pazopanib or Methotrexate-Vinblastine Combination Chemotherapy in Adult Patients with Progressive Desmoid Tumours (DESMOPAZ): A Non-Comparative, Randomised, Open-Label, Multicentre, Phase 2 Study","volume":"20","author":"Toulmonde","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1200\/JCO.2017.73.5324","article-title":"Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo after Nephrectomy in Patients with Localized or Locally Advanced Renal Cell Carcinoma","volume":"35","author":"Motzer","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for Metastatic Soft-Tissue Sarcoma (PALETTE): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial","volume":"379","author":"Blay","year":"2012","journal-title":"Lancet"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Berardi, R., Santoni, M., Rinaldi, S., Nunzi, E., Smerilli, A., Caramanti, M., Morgese, F., Torniai, M., Savini, A., and Fiordoliva, I. (2016). Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0152079"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S1470-2045(12)70335-2","article-title":"Vandetanib in Locally Advanced or Metastatic Differentiated Thyroid Cancer: A Randomised, Double-Blind, Phase 2 Trial","volume":"13","author":"Leboulleux","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial","volume":"30","author":"Wells","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S2213-2600(16)30322-8","article-title":"Vandetanib in Patients with Previously Treated RET-Rearranged Advanced Non-Small-Cell Lung Cancer (LURET): An Open-Label, Multicentre Phase 2 Trial","volume":"5","author":"Yoh","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/ERC-18-0258","article-title":"Safety and Efficacy of Two Starting Doses of Vandetanib in Advanced Medullary Thyroid Cancer","volume":"26","author":"Hu","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.2011.36.1709","article-title":"Vandetanib Versus Placebo in Patients with Advanced Non-Small-Cell Lung Cancer after Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)","volume":"30","author":"Lee","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1158\/1078-0432.CCR-12-0411","article-title":"Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary","volume":"18","author":"Thornton","year":"2012","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative Effectiveness of Axitinib versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdy454","article-title":"Axitinib versus Placebo as an Adjuvant Treatment of Renal Cell Carcinoma: Results from the Phase III, Randomized ATLAS Trial","volume":"29","author":"Kwon","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","article-title":"Axitinib versus Sorafenib as Second-Line Treatment for Advanced Renal Cell Carcinoma: Overall Survival Analysis and Updated Results from a Randomised Phase 3 Trial","volume":"14","author":"Motzer","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S1470-2045(13)70465-0","article-title":"Axitinib versus Sorafenib as First-Line Therapy in Patients with Metastatic Renal-Cell Carcinoma: A Randomised Open-Label Phase 3 Trial","volume":"14","author":"Hutson","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1634\/theoncologist.2018-0072","article-title":"Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study","volume":"24","author":"Martinelli","year":"2019","journal-title":"Oncologist"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/jgh.14974","article-title":"Regorafenib in Chinese Patients with Metastatic Colorectal Cancer: Subgroup Analysis of the Phase 3 CONCUR Trial","volume":"35","author":"Xu","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer (CORRECT): An International, Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma","volume":"379","author":"Meyer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1470-2045(20)30202-3","article-title":"Cabozantinib in Patients with Platinum-Refractory Metastatic Urothelial Carcinoma: An Open-Label, Single-Centre, Phase 2 Trial","volume":"21","author":"Apolo","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"Cabozantinib in Patients with Advanced RET-Rearranged Non-Small-Cell Lung Cancer: An Open-Label, Single-Centre, Phase 2, Single-Arm Trial","volume":"17","author":"Drilon","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(19)30825-3","article-title":"Cabozantinib in Patients with Advanced Ewing Sarcoma or Osteosarcoma (CABONE): A Multicentre, Single-Arm, Phase 2 Trial","volume":"21","author":"Italiano","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1634\/theoncologist.2020-0127","article-title":"A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone Metastases","volume":"25","author":"Xu","year":"2020","journal-title":"Oncologist"},{"key":"ref_92","first-page":"346","article-title":"Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non-Small-Cell Lung Cancer","volume":"10","author":"Okamoto","year":"2015","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Yamazaki, H., Iwasaki, H., Takasaki, H., Suganuma, N., Sakai, R., Masudo, K., Nakayama, H., Rino, Y., and Masuda, M. (2019). Efficacy and Tolerability of Initial Low-Dose Lenvatinib to Treat Differentiated Thyroid Cancer. Medicine, 98.","DOI":"10.1097\/MD.0000000000014774"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1177\/1078155215592023","article-title":"Tyrosine Kinase Inhibitor-Associated Syndrome of Inappropriate Secretion of Anti-Diuretic Hormone","volume":"22","author":"Hill","year":"2016","journal-title":"J. Oncol. Pharm. Pract. Off. Publ. Int. Soc. Oncol. Pharm. Pract."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1158\/1078-0432.CCR-09-0224","article-title":"Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors","volume":"15","author":"Demetri","year":"2009","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukaemia: An International, Randomised, Open-Label, Phase 3 Trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib Efficacy and Safety in Philadelphia Chromosome-Positive Leukemia: Final 5-Year Results of the Phase 2 PACE Trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Degirmenci, U., Wang, M., and Hu, J. (2020). Targeting Aberrant RAS\/RAF\/MEK\/ERK Signaling for Cancer Therapy. Cells, 9.","DOI":"10.3390\/cells9010198"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.ajkd.2016.12.013","article-title":"BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome","volume":"70","author":"Perico","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"F93","DOI":"10.1152\/ajprenal.00345.2007","article-title":"Identification of BRAF as a New Interactor of PLCepsilon1, the Protein Mutated in Nephrotic Syndrome Type 3","volume":"294","author":"Chaib","year":"2008","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ckj\/sfv149","article-title":"Renal Effects of BRAF Inhibitors: A Systematic Review by the Cancer and the Kidney International Network","volume":"9","author":"Wanchoo","year":"2016","journal-title":"Clin. Kidney J."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/j.1523-1755.2005.00575.x","article-title":"VEGF Regulation of Endothelial Nitric Oxide Synthase in Glomerular Endothelial Cells","volume":"68","author":"Feliers","year":"2005","journal-title":"Kidney Int."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1183\/13993003.01110-2015","article-title":"Pulmonary Hypertension Associated with Ponatinib Therapy","volume":"47","author":"Quilot","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular Toxic Effects of Targeted Cancer Therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_106","first-page":"2503","article-title":"Vascular Toxicity Associated with Anti-Angiogenic Drugs","volume":"134","author":"Neves","year":"2020","journal-title":"Clin. Sci. Lond. Engl. 1979"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin Inhibits Primary and Metastatic Tumor Growth by Antiangiogenesis: Involvement of Vascular Endothelial Growth Factor","volume":"8","author":"Guba","year":"2002","journal-title":"Nat. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fonc.2014.00064","article-title":"Targeting PI3K\/Akt\/MTOR Signaling in Cancer","volume":"4","author":"Porta","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13045-019-0754-1","article-title":"Targeting MTOR for Cancer Therapy","volume":"12","author":"Hua","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Magaway, C., Kim, E., and Jacinto, E. (2019). Targeting MTOR and Metabolism in Cancer: Lessons and Innovations. Cells, 8.","DOI":"10.3390\/cells8121584"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Comunanza, V., and Bussolino, F. (2017). Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies. Front. Cell Dev. Biol., 5.","DOI":"10.3389\/fcell.2017.00101"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrd4591","article-title":"Combination Cancer Immunotherapy and New Immunomodulatory Targets","volume":"14","author":"Mahoney","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm.3541","article-title":"Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors","volume":"20","author":"Motz","year":"2014","journal-title":"Nat. Med."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Kudo, M. (2018). Systemic Therapy for Hepatocellular Carcinoma: Latest Advances. Cancers, 10.","DOI":"10.3390\/cancers10110412"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a Biomarker of Efficacy in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cncr.28972","article-title":"Clinical Risk Factors for the Development of Hypertension in Patients Treated with Inhibitors of the VEGF Signaling Pathway","volume":"121","author":"Hamnvik","year":"2015","journal-title":"Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of Proteinuria and Hypertension with Bevacizumab, an Antibody against Vascular Endothelial Growth Factor: Systematic Review and Meta-Analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am. J. Kidney Dis. Off. J. Natl. Kidney Found."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/HYPERTENSIONAHA.109.129973","article-title":"Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression","volume":"54","author":"Facemire","year":"2009","journal-title":"Hypertension"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11912-012-0242-z","article-title":"VEGF Inhibition, Hypertension, and Renal Toxicity","volume":"14","author":"Hayman","year":"2012","journal-title":"Curr. Oncol. Rep."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s11906-999-0016-7","article-title":"Role of Nitric Oxide in the Control of Renal Function and Salt Sensitivity","volume":"1","author":"Zou","year":"1999","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1097\/HJH.0000000000001650","article-title":"The Role of Distal Tubule and Collecting Duct Sodium Reabsorption in Sunitinib-Induced Hypertension","volume":"36","author":"Witte","year":"2018","journal-title":"J. Hypertens."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1097\/HJH.0000000000000326","article-title":"Rho Kinase Inhibition Mitigates Sunitinib-Induced Rise in Arterial Pressure and Renal Vascular Resistance but Not Increased Renal Sodium Reabsorption","volume":"32","author":"Grisk","year":"2014","journal-title":"J. Hypertens."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"F905","DOI":"10.1152\/ajprenal.2000.278.6.F905","article-title":"Vascular Endothelial Growth Factor Is a Survival Factor for Renal Tubular Epithelial Cells","volume":"278","author":"Kanellis","year":"2000","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/ajh.2012.97","article-title":"Regorafenib Induces Rapid and Reversible Changes in Plasma Nitric Oxide and Endothelin-1","volume":"25","author":"Robinson","year":"2012","journal-title":"Am. J. Hypertens."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","article-title":"Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated with Increased Circulating Endothelin-1 Levels","volume":"56","author":"Kappers","year":"2010","journal-title":"Hypertension"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1161\/HYPERTENSIONAHA.111.173559","article-title":"The Vascular Endothelial Growth Factor Receptor Inhibitor Sunitinib Causes a Preeclampsia-like Syndrome with Activation of the Endothelin System","volume":"58","author":"Kappers","year":"2011","journal-title":"Hypertension"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1161\/HYPERTENSIONAHA.115.05435","article-title":"Greater Sensitivity of Blood Pressure Than Renal Toxicity to Tyrosine Kinase Receptor Inhibition With Sunitinib","volume":"66","author":"Lankhorst","year":"2015","journal-title":"Hypertension"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/ncpneph0891","article-title":"Reversal of Proteinuric Renal Disease and the Emerging Role of Endothelin","volume":"4","author":"Barton","year":"2008","journal-title":"Nat. Clin. Pract. Nephrol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1681\/ASN.2013040362","article-title":"\u03b2-Arrestin-1 Drives Endothelin-1-Mediated Podocyte Activation and Sustains Renal Injury","volume":"25","author":"Buelli","year":"2014","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"R230","DOI":"10.1152\/ajpregu.00373.2015","article-title":"Endothelin-1 and Antiangiogenesis","volume":"310","author":"Lankhorst","year":"2016","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1089\/ars.2008.2118","article-title":"Oxidative Stress Impairs Endothelial Progenitor Cell Function","volume":"10","author":"Case","year":"2008","journal-title":"Antioxid. Redox Signal."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"H547","DOI":"10.1152\/ajpheart.00616.2005","article-title":"Cellular Changes in Normal Blood Capillaries Undergoing Regression after Inhibition of VEGF Signaling","volume":"290","author":"Baffert","year":"2006","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"H560","DOI":"10.1152\/ajpheart.00133.2005","article-title":"VEGF-Dependent Plasticity of Fenestrated Capillaries in the Normal Adult Microvasculature","volume":"290","author":"Kamba","year":"2006","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/annonc\/mdm550","article-title":"Blood Pressure Rise Following Angiogenesis Inhibition by Bevacizumab. A Crucial Role for Microcirculation","volume":"19","author":"Mourad","year":"2008","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"20089","DOI":"10.1038\/srep20089","article-title":"The Influence of Genetic Variants of Sorafenib on Clinical Outcomes and Toxic Effects in Patients with Advanced Renal Cell Carcinoma","volume":"6","author":"Qin","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_137","first-page":"503","article-title":"Polymorphisms in Endothelial Nitric Oxide Synthase (ENOS) and Vascular Endothelial Growth Factor (VEGF) Predict Sunitinib-Induced Hypertension","volume":"92","author":"Eechoute","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1002\/cncr.26491","article-title":"Association of VEGF and VEGFR2 Single Nucleotide Polymorphisms with Hypertension and Clinical Outcome in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated with Sunitinib","volume":"118","author":"Kim","year":"2012","journal-title":"Cancer"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1200\/JCO.2008.16.1612","article-title":"Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms with Outcome in a Trial of Paclitaxel Compared with Paclitaxel plus Bevacizumab in Advanced Breast Cancer: ECOG 2100","volume":"26","author":"Schneider","year":"2008","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_140","first-page":"331","article-title":"Vascular Endothelial Growth Factor A c.*237C>T Polymorphism Is Associated with Bevacizumab Efficacy and Related Hypertension in Metastatic Colorectal Cancer","volume":"47","author":"Mancini","year":"2015","journal-title":"Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/tpj.2016.25","article-title":"Endothelin-1 Genetic Polymorphism as Predictive Marker for Bevacizumab in Metastatic Breast Cancer","volume":"17","author":"Gampenrieder","year":"2017","journal-title":"Pharmacogenom. J."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A Randomized Trial of Bevacizumab, an Anti-Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF Signalling Inhibition-Induced Proteinuria: Mechanisms, Significance and Management","volume":"46","author":"Izzedine","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1056\/NEJMra052131","article-title":"Hereditary Proteinuria Syndromes and Mechanisms of Proteinuria","volume":"354","author":"Tryggvason","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41379-018-0186-4","article-title":"Bevacizumab-Associated Glomerular Microangiopathy","volume":"32","author":"Person","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc2152","article-title":"Possible Molecular Mechanisms Involved in the Toxicity of Angiogenesis Inhibition","volume":"7","author":"Verheul","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1158\/0008-5472.CAN-04-3156","article-title":"In Vitro Procoagulant Activity Induced in Endothelial Cells by Chemotherapy and Antiangiogenic Drug Combinations: Modulation by Lower-Dose Chemotherapy","volume":"65","author":"Ma","year":"2005","journal-title":"Cancer Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00467-010-1637-4","article-title":"Advances in Our Understanding of the Pathogenesis of Glomerular Thrombotic Microangiopathy","volume":"26","author":"Keir","year":"2011","journal-title":"Pediatr. Nephrol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2215\/CJN.00620117","article-title":"Thrombotic Microangiopathy and the Kidney","volume":"13","author":"Brocklebank","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1172\/JCI86418","article-title":"VEGF Regulates Local Inhibitory Complement Proteins in the Eye and Kidney","volume":"127","author":"Keir","year":"2017","journal-title":"J. Clin. Invest."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1056\/NEJMra1106556","article-title":"Focal Segmental Glomerulosclerosis","volume":"365","author":"Kaskel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1681\/ASN.2017090958","article-title":"Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach","volume":"29","author":"Sethi","year":"2018","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1681\/ASN.2015091048","article-title":"Nephrin Tyrosine Phosphorylation Is Required to Stabilize and Restore Podocyte Foot Process Architecture","volume":"27","author":"New","year":"2016","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/S0002-9440(10)61782-8","article-title":"Involvement of Lipid Rafts in Nephrin Phosphorylation and Organization of the Glomerular Slit Diaphragm","volume":"159","author":"Simons","year":"2001","journal-title":"Am. J. Pathol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/sj.ki.5000439","article-title":"Blockade of VEGF Accelerates Proteinuria, via Decrease in Nephrin Expression in Rat Crescentic Glomerulonephritis","volume":"69","author":"Hara","year":"2006","journal-title":"Kidney Int."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Terrasse, M. (2015). Anti-VEGF Therapy Induces Proteinuria through Endothelial Disorganization Leading to Nephrin Decrease in Podocytes. Int. J. Immunother. Cancer Res., 021\u2013028.","DOI":"10.17352\/2455-8591.000006"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"ra39","DOI":"10.1126\/scisignal.2000678","article-title":"C-Mip Impairs Podocyte Proximal Signaling and Induces Heavy Proteinuria","volume":"3","author":"Zhang","year":"2010","journal-title":"Sci. Signal."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/cncr.22904","article-title":"Renal Insufficiency and Cancer Medications (IRMA) Study Group Prevalence of Renal Insufficiency in Cancer Patients and Implications for Anticancer Drug Management: The Renal Insufficiency and Anticancer Medications (IRMA) Study","volume":"110","author":"Oudard","year":"2007","journal-title":"Cancer"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMra1613984","article-title":"Acute Kidney Injury in Patients with Cancer","volume":"376","author":"Rosner","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.kint.2020.06.046","article-title":"KDIGO Controversies Conference on Onco-Nephrology: Understanding Kidney Impairment and Solid-Organ Malignancies, and Managing Kidney Cancer","volume":"98","author":"Porta","year":"2020","journal-title":"Kidney Int."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/ckj\/sft135","article-title":"Nephrotoxicity of Recent Anti-Cancer Agents","volume":"7","author":"Lameire","year":"2014","journal-title":"Clin. Kidney J."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41392-020-0199-6","article-title":"Targeted Therapies in Gynecological Cancers: A Comprehensive Review of Clinical Evidence","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa1111097","article-title":"Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer","volume":"366","author":"Bear","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/annonc\/mds590","article-title":"Systematic Review and Meta-Analysis of Randomised, Phase II\/III Trials Adding Bevacizumab to Platinum-Based Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer","volume":"24","author":"Soria","year":"2013","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"293.e1","DOI":"10.1016\/j.urolonc.2016.02.018","article-title":"Trends of Acute Kidney Injury after Radical or Partial Nephrectomy for Renal Cell Carcinoma","volume":"34","author":"Schmid","year":"2016","journal-title":"Urol. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrneph.2013.273","article-title":"Risk of Chronic Kidney Disease after Cancer Nephrectomy","volume":"10","author":"Li","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"17088","DOI":"10.1038\/nrdp.2017.88","article-title":"Chronic Kidney Disease","volume":"3","author":"Romagnani","year":"2017","journal-title":"Nat. Rev. Dis. Primer"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic Kidney Disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Piscitani, L., Sirolli, V., Di Liberato, L., Morroni, M., and Bonomini, M. (2020). Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21144878"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41581-018-0003-9","article-title":"Advances in Predictive in Vitro Models of Drug-Induced Nephrotoxicity","volume":"14","author":"Soo","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.dmpk.2019.02.006","article-title":"Estimation of Changes in Serum Creatinine and Creatinine Clearance Caused by Renal Transporter Inhibition in Healthy Subjects","volume":"34","author":"Nakada","year":"2019","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1124\/dmd.113.053215","article-title":"Assessment of Vandetanib as an Inhibitor of Various Human Renal Transporters: Inhibition of Multidrug and Toxin Extrusion as a Possible Mechanism Leading to Decreased Cisplatin and Creatinine Clearance","volume":"41","author":"Shen","year":"2013","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Tanihara, Y., Masuda, S., and Inui, K.-I. (2020). European Journal of Pharmaceutical Sciences: PHASCI-D-20-01517R2Inhibitory Effects of Vandetanib on Creatinine Transport via Renal Organic Cation Transporter OCT2. Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci., 105666.","DOI":"10.1016\/j.ejps.2020.105666"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/annonc\/mdr525","article-title":"Sorafenib-Induced Diarrhea and Hypophosphatemia: Mechanisms and Therapeutic Implications","volume":"23","author":"Mir","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Xiao, J., Wang, J., Yuan, L., Hao, L., and Wang, D. (2019). Study on the Mechanism and Intervention Strategy of Sunitinib Induced Nephrotoxicity. Eur. J. Pharmacol., 864.","DOI":"10.1016\/j.ejphar.2019.172709"},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Liu, N., Xu, L., Shi, Y., and Zhuang, S. (2017). Podocyte Autophagy: A Potential Therapeutic Target to Prevent the Progression of Diabetic Nephropathy. J. Diabetes Res., 2017.","DOI":"10.1155\/2017\/3560238"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/bjc.2013.420","article-title":"Pazopanib and Sunitinib Trigger Autophagic and Non-Autophagic Death of Bladder Tumour Cells","volume":"109","author":"Santoni","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1158\/1535-7163.MCT-08-0669","article-title":"Dasatinib-Induced Autophagy Is Enhanced in Combination with Temozolomide in Glioma","volume":"8","author":"Milano","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1038\/cddis.2013.18","article-title":"Mcl-1-Dependent Activation of Beclin 1 Mediates Autophagic Cell Death Induced by Sorafenib and SC-59 in Hepatocellular Carcinoma Cells","volume":"4","author":"Tai","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1080\/15548627.2019.1705007","article-title":"Podocytes Maintain High Basal Levels of Autophagy Independent of Mtor Signaling","volume":"16","author":"Bork","year":"2020","journal-title":"Autophagy"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1172\/JCI44774","article-title":"Role of MTOR in Podocyte Function and Diabetic Nephropathy in Humans and Mice","volume":"121","author":"Hartleben","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1681\/ASN.2011070690","article-title":"Inhibition of MTOR Disrupts Autophagic Flux in Podocytes","volume":"23","author":"Onay","year":"2012","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1080\/15548627.2015.1049799","article-title":"Endothelial Cell and Podocyte Autophagy Synergistically Protect from Diabetes-Induced Glomerulosclerosis","volume":"11","author":"Lenoir","year":"2015","journal-title":"Autophagy"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.nephro.2008.10.002","article-title":"Vascular and renal effects of anti-angiogenic therapy","volume":"4","author":"Halimi","year":"2008","journal-title":"Nephrol. Ther."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/11\/4\/640\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:10:56Z","timestamp":1760364656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/11\/4\/640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":184,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["diagnostics11040640"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics11040640","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]}}}